Sai Parenteral's Limited SAIPARENT NSEPHARMA
Company Overview
Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, oncology, and dermatology in various dosage forms, including injectables, solid orals, liquid orals, and topicals. The company was founded in 1988 and is based in Hyderabad, India.
Why Investors Should Care
Return on capital employed stands at 17.9%.
Net profit has compounded at 111.8% per year over the last five years.
Revenue has grown at a 126.1% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of ₹381.00 Cr (-23.0% YoY); net profit ₹14.00 Cr.
- Trailing 12 Months Year-on-year growth — revenue +435.1%, earnings +1527.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 126.1%, profit CAGR 111.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 126.13% |
| 1 Year: | 435.10% |
Compounded Profit Growth
| 5 Years: | 111.79% |
| 1 Year: | 1,527.30% |
Stock Price Performance
| 1 Year: | +15.26% |
| 6 Months: | -3.54% |
| 3 Months: | -13.36% |
| 1 Month: | -8.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)33.45 · Neutral
P/E of 161.24 is above the sector median of 36.43 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 126.1% over 5 years.
- Profit CAGR of 111.8% over 5 years.
CONS
- Trading at a high P/E of 161.2.
- Trading 25.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SAIPARENT Sai Parenteral's Limited NSEPHARMA | 467.60 | 161.24 | ₹2,065.82 Cr | 0.00% | 17.92% | 2.85% | 126.13% | 111.79% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2025 | Mar 2026 |
|---|---|---|
| Revenue | 96.00 Cr | 198.00 Cr |
| Operating Expenses | 100.00 Cr | 172.00 Cr |
| Operating Income | -10.00 Cr | 18.00 Cr |
| EBITDA | -4.00 Cr | 26.00 Cr |
| Interest Expense | 5.00 Cr | 8.00 Cr |
| Pretax Income | -12.00 Cr | 12.00 Cr |
| Tax Provision | 5.16 Cr | -72.00 L |
| Net Income | -7.00 Cr | 13.00 Cr |
| Diluted EPS | -1.80 | 2.98 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 96.80 Cr | 153.76 Cr | 494.96 Cr | 381.00 Cr |
| Cost of Revenue | 57.95 Cr | 94.97 Cr | 270.27 Cr | - |
| Gross Profit | 38.84 Cr | 58.80 Cr | 224.69 Cr | - |
| Operating Expenses | 22.13 Cr | 33.05 Cr | 193.08 Cr | 342.00 Cr |
| Operating Income | 16.72 Cr | 25.75 Cr | 31.61 Cr | 22.00 Cr |
| EBITDA | 18.77 Cr | 33.10 Cr | 54.35 Cr | 39.00 Cr |
| Interest Expense | 5.72 Cr | 11.12 Cr | 16.52 Cr | 18.00 Cr |
| Pretax Income | 7.25 Cr | 12.55 Cr | 27.85 Cr | 12.00 Cr |
| Tax Provision | 2.88 Cr | 4.14 Cr | 8.22 Cr | -2.40 Cr |
| Net Income | 4.38 Cr | 8.41 Cr | 19.63 Cr | 14.00 Cr |
| Diluted EPS | 0.99 | 1.90 | 4.44 | 3.23 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 133.96 Cr | 268.10 Cr | 723.58 Cr | 1,424.00 Cr |
| Current Assets | 81.94 Cr | 187.35 Cr | 384.54 Cr | - |
| Cash & Equivalents | 17.30 L | 4.38 Cr | 8.15 Cr | - |
| Inventory | 13.19 Cr | 37.21 Cr | 151.33 Cr | - |
| Receivables | 61.21 Cr | 127.06 Cr | 196.52 Cr | - |
| Total Liabilities | 102.48 Cr | 191.70 Cr | 599.97 Cr | - |
| Current Liabilities | 76.63 Cr | 152.76 Cr | 476.00 Cr | - |
| Long Term Debt | 25.64 Cr | 38.70 Cr | 123.46 Cr | - |
| Total Debt | 68.55 Cr | 118.78 Cr | 203.66 Cr | 333.00 Cr |
| Total Equity | 31.48 Cr | 74.55 Cr | 111.49 Cr | 491.00 Cr |
| Shares Outstanding | 4.42 Cr | 4.42 Cr | 4.42 Cr | - |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -12.80 Cr | -29.76 Cr | 33.15 Cr | 93.00 Cr |
| Investing Cash Flow | -19.03 Cr | -46.32 Cr | 43.50 L | -274.00 Cr |
| Financing Cash Flow | 23.98 Cr | 78.57 Cr | -35.88 Cr | 596.00 Cr |
| Capital Expenditure | -17.34 Cr | -44.10 Cr | -50.00 L | -277.00 Cr |
| Free Cash Flow | -30.14 Cr | -73.86 Cr | 32.65 Cr | -184.00 Cr |
| Net Change in Cash | -7.85 Cr | 2.48 Cr | -2.30 Cr | 415.00 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 40.1% | 38.2% | 45.4% | - |
| Operating Margin % | 17.3% | 16.7% | 6.4% | 5.8% |
| Net Margin % | 4.5% | 5.5% | 4.0% | 3.7% |
| ROE % | 13.9% | 11.3% | 17.6% | 2.9% |
| ROCE % | 29.2% | 22.3% | 12.8% | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SAIPARENT
SAIPARENT Stock Price and Chart — NSE:SAIPARENT - TradingView
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1kcS1lTm45bTNBZmpsdW1FRDBEZEs0WktjUlNrandOS3dHc09fTEpocWo5NmdDNGhLQ3BXcUUtQXc4VTB2aW1XNExIeXFrOUFoMWd6b2ZVR1U4WDdodVBR?oc=5" target="_blank">SAIPARENT Stock Price and Chart — NSE:S…
Sai Parenteral's (NSEI:SAIPARENT) - Stock Analysis - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPb1JEM1FlaTN3aEtPWjJaMzJxLWtNTl9lY05OMEt6TU5RdHg2bUhUcFVBUkxYU3VieGMyMUpENUY2N0QtYUZsamdFZVZGZGFCMnNPdW9xMzZXWEh6d0ZpQnd5RUhVdnkwMkxaRlZfOU11WU1paDFIRkdzSHdHVlpnUDd4UG9DenNnVWZIdz…
SAI PARENTERALS LIMITED Share Price - Live NSE: SAIPARENT Stock Price & Chart - Upstox
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE40ZGFmNWN5M1l3TDRvbkZ4YncyRkp5LWVDd1ROWm00emxPVUx6TE9HTE42QWREV3BCY1BFSVNYRVNrUldDcWJFdHlYWmZ6a1NVOFpfQVRlX0pWWTN2Z2F2b3doZ0ZZb1dMY3FKX19nTQ?oc=5" target="_blank">SAI PARENTERALS L…
SAIPARENT.NS Q2 FY2025 Earnings: Robust Revenue Growth Amidst Marginal Stock Decline - CFO Commentary Report - siam.in
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSlY3azc4UG9wZllBYUJSSkExMmVaQ3g3Umx6N1ZNcFZtZ0NhdWMtTTV1Z0JDNlZRSHN4U0FDSGtiU1d3dFJlTldlclFxdUVQSC1iOFN0bmo5TERCY2VZMEtLSEozWDJycDB4OF94djV5WnRhOU1wZzhjTGVOZUpLeFg0ZDJaa0U2SjJsZV…
Sai Parenterals Ltd | Stock Share Price Live - MarketSmith India
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1VSENTcTFtTGdwSng4TXFlbGdBeElkblY3R0dzSE9aMlRSdmZ6QVEybEFtSnBlTzJOX0hib3hHUDJiX1AyYmVZcXMtUXpHZncxdVl2d0FKdHJ1cTZCZGRyejNwcllnTFd0dml4OGQ5SFYwdXoweFdCVmZn?oc=5" target="_blank">Sai…
Sai Parenterals Schedules July 2 Investor Meet to Discuss 18% Revenue Growth Guidance - Sahi
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNUzc2WW44My1WRGZqSlcyYkNuRjNneUJwaExTNlRjSVREQmdGWkhDakdFVnVJWDlJNEJ5a2xMcldPNkNVSmRBeUwyajVqdkY3YzRzMkJqTFFnWGJuR0V1c1ZxdWgtSXFMbjNMNjhNSjRrUjlTOEN3eFJfOWt4SmxURnBXQ1lTTmM1YUV5Zk…
SAIPARENT — Frequently Asked Questions
What is the current share price of Sai Parenteral's Limited (SAIPARENT)?
As of 2026-10-23 04:58 IST, Sai Parenteral's Limited (SAIPARENT) trades at ₹467.60 on NSE. Its 52-week range is ₹405.70 to ₹623.80.
What is the market capitalisation of SAIPARENT?
Sai Parenteral's Limited (SAIPARENT) has a market capitalisation of ₹2,065.82 Cr on NSE.
What is the P/E ratio of SAIPARENT?
SAIPARENT trades at a trailing price-to-earnings (P/E) ratio of 161.24. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 3.29.
What is the return on equity (ROE) of SAIPARENT?
SAIPARENT has a return on equity (ROE) of 2.85%. Its return on capital employed (ROCE) is 17.92%.
Is SAIPARENT a good stock to buy?
This page provides a data-driven analysis of Sai Parenteral's Limited (SAIPARENT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.